Ingersoll Rand's (IR) standing in the investment sphere has evolved recently. Several financial entities, including Barclays, sustain their buy rating for IR, offering
optimism about the U.S. Manufacturing Recovery. There have been fluctuations with entities such as Tema Etfs LLC and Allspring Global Investments modifying their positions in IR. The
Q4 Earnings have displayed mixed results compared to other players in the Gas and Liquid Handling stocks. A temporary dip in IR's stock price led to a
price target decrease to $90.00 and debates surrounding the firm's P/E multiple. Barclays revised its price target to $100, revealing the stock's dynamic nature. The Scinomix deal and IR's better-than-expected sales in Q4 CY2025 are seen as strong points, shifting the investment narrative. Despite potential risks, several investment firms, including Nordea Investment Management, Russell Investments Group and Hudson Bay Capital Management, increased their shares. However, negative factors persist such as IR's compression tests questioning bullish earnings growth narrative and Swiss National Bank selling 57,200 IR shares. Nevertheless, the positive outlook for 2026 hints at room for growth.
Ingersoll Rand IR News Analytics from Thu, 10 Jul 2025 07:00:00 GMT to Fri, 03 Apr 2026 03:38:00 GMT -
Rating 3
- Innovation -2
- Information 7
- Rumor -1
